Rose McNulty

FDA grants lunsotogene parvec-cwha approval for OTOF-related hearing loss, delivering single-dose gene therapy gains and expanding access with free US supply.

The FDA approved dupilumab for children aged 2 to 11 years with uncontrolled CSU—the first biologic for this pediatric population.

DELTA 3 trial extension data show sustained improvements in disease-specific, dermatology-specific, and overall quality-of-life measures.

Steven Kheloussi, PharmD, explains how care coordination and transparent policies can improve MS treatment adherence, streamline access, and balance costs.

Nancy L. Lewis, MD, MBS, FACP, discusses her path from the clinic to biopharma and her goals as NCCN's new CSO, including health equity and faster drug development.

Steven Kheloussi, PharmD, explores how smarter clinical tools, multidisciplinary teams, and better care coordination can improve outcomes for people with MS.

Fewer than half of phase 3 chronic spontaneous urticaria (CSU) trials reported baseline disease duration, a review found.

Expert guidance shows how to safely tailor aesthetic dermatology for allergic skin conditions like urticaria and eczema.

Fred D. Lublin, MD, discusses therapy sequencing, deescalation, health equity, and the future of multiple sclerosis (MS) care delivery.

Icotrokinra is the first and only interleukin-23–targeted oral peptide approved for plaque psoriasis.

Secukinumab becomes the only IL-17A inhibitor approved for this population and the first new mechanism in the indication in nearly a decade.

The mental health burden of vitiligo closely resembles atopic dermatitis but differs significantly from psoriasis, a study suggests.

GPT-4o reliably scored alopecia areata severity from scalp images, showing strong concordance with experienced dermatology providers without prior AI training.

Fred D. Lublin, MD, discusses evolving concepts in MS, including earlier high-efficacy therapy, unrecognized progression, and emerging outcome measures.

Recent guideline updates for squamous cell skin cancer add adjuvant cemiplimab as a preferred option for certain patients with very high-risk disease.

ACOs entering MSSP with higher spending were consistently more likely to earn bonuses—a gap that persisted after a 2017 benchmarking policy change.

Elevance Health's Shane Hochradel explains how the company tracks provider satisfaction and uses AI to cut administrative burden.

Study links moderate to severe alopecia areata to higher atopic dermatitis risk, urging routine screening and smarter treatment choices.

The approval, dupilumab's ninth in the US, is supported by the phase 3 LIBERTY-AFRS-AIMS trial.

Kavita Nair, PhD, discusses how clinicians select MS therapies, the role of cost and access, and why policy changes could threaten patient outcomes.

Reform priorities aim to reshape PBM oversight, delink compensation from drug prices, boost transparency, and protect pharmacy access.

Catherine Gaffigan, MD, Elevance Health's President of Health Solutions, discusses value-based care initiatives and payer-provider relationships.

A new patient decision aid uses a staged approach to help adults with moderate to severe atopic dermatitis choose systemic treatments effectively.

OCEANIC-STROKE shows asundexian cuts recurrent ischemic stroke risk across noncardioembolic subtypes without increasing major bleeding risk.

OCEANIC-STROKE shows asundexian cuts ischemic stroke recurrence by 26% in patients taking standard antiplatelet therapy, with no major bleeding increase.

Major and minor risk factors, including early eczema and delayed food introduction, shape childhood food allergy risk, a review found.

A new psoriasis severity tool called G2-PASE showed a strong correlation with PASI, potentially offering a simpler assessment for clinical practice.

Key takeaways from ISC 2026 included positive outcomes in stroke prevention, postthrombectomy care, and the return of neuroprotection.

Kavita Nair, PhD, discusses integrating neurology and pharmacy services to improve MS care coordination and reduce treatment delays.

The FDA approved Optune Pax, a first-of-its-kind portable device delivering tumor-treating fields for locally advanced pancreatic cancer treatment at home.